Shilpa Medicare buys 30% of Spanish biotech for €7M, chases a brain-cancer therapy
Its unit Shilpa Biocare acquires a minority stake in Gate2Brain, gaining manufacturing rights for a candidate with orphan drug status from the FDA and EMA.
— 8 earlier stories on Shilpa Medicare Ltd. →What's new
- Shilpa Biocare is buying 30.4% of Spanish biotech Gate2Brain for €7M.
- The deal gives Shilpa exclusive manufacturing and regulatory support rights for G2B-002, a brain-cancer therapy.
- G2B-002 has orphan drug designation from both the FDA and EMA for two childhood brain cancers.
Why this matters
The deal gives Shilpa a foothold in central-nervous-system drug delivery via a proprietary peptide shuttle. But the investment is only about 0.6% of its market cap, so it's a long-biotech-horizon bet rather than a near-term revenue driver. The real payoff, if any, is years away.
What we're watching
- Whether Shilpa can translate the manufacturing rights into a meaningful commercial role if G2B-002 succeeds.
- Progress toward first-in-human trials by FY28.
- How the €7M investment fits into Shilpa's broader pipeline spending.
The full read
Shilpa Medicare is paying €7 million for a 30.4% stake in Spanish biotech Gate2Brain. The prize isn't the equity. It's the exclusive manufacturing and regulatory support rights for G2B-002, a therapy for diffuse intrinsic pontine glioma and pediatric glioblastoma that uses a peptide shuttle to cross the blood-brain barrier. Both the FDA and EMA have granted it orphan drug status, a designation for rare diseases that can speed regulatory review. The catch: first-in-human trials aren't expected to start until FY28, and the €7 million outlay is only about 0.6% of Shilpa's market cap. This is a pipeline option, not a revenue catalyst. For a mid-cap drug maker, the move signals interest in advanced delivery tech, but the commercial verdict is years out.
Questions answered
- What is Shilpa getting for its money?
- Shilpa Biocare acquires a 30.4% stake in Gate2Brain and the exclusive right to manufacture and support regulatory filings for G2B-002, a therapy for aggressive childhood brain cancers.
- How significant is the €7M investment for Shilpa?
- The investment represents only about 0.6% of Shilpa Medicare's market capitalization, making it financially minor in the near term.
- What is special about the G2B-002 therapy?
- It uses a proprietary peptide shuttle to deliver a potent anticancer agent across the blood-brain barrier. The therapy has received orphan drug designation from both the FDA and the EMA.
- When will we see clinical results?
- First-in-human clinical trials are targeted to begin by FY28, meaning any efficacy or safety data is at least two years away.
Shilpa Medicare Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SHILPAMED →- 3 Jun 2026 · 9:31 AM IST Shilpa Medicare buys 30% of Spanish biotech for €7M, chases a brain-cancer therapy
- 8d ago Shilpa Medicare loses biologics CEO at key growth phase
- 16d ago Shilpa Medicare lands credit upgrade to IND AA-
- 23d ago Shilpa Medicare partners with Orion for Nivolumab biosimilar in Europe
- 29d ago Shilpa Medicare commissions ADC facility, targets global CDMO play